Saccharomyces boullardii 30 capsules (9 billion CFU/capsule)

25.00

The use of Saccharomyces boulardii, a beneficial yeast probiotic, has been shown as a positive treatment of acute gastroenteritis1, enhancing the immune response2, and the prevention of antibiotic-associated diarrhoea in the pediatric population3. S. boullardii has been shown to prevent antibiotic-associated diarrhoea (AAD) known as traveler’s diarrhoea4, as well as the use of this yeast probiotic for the prevention of enteral nutrition-related diarrhoea5. This yeast is best known in the treatment against H. pylori infection6, as well as the prevention of antibiotic-associated diarrhoea7 due to the infection in adults and children8. In infants, S. boullardii has shown promise in C. difficile-associated enteropathies9, the prevention of C. difficile disease recurrences10 when combined with other treatment methods11. Intake of the probiotic has shown to assist in the maintenance of Crohn’s disease11, ulcerative colitis12, post-treatment for antibiotic-associated diarrhoea13, as well as reduce dysbiosis caused by specific antibiotics15.

Description

Dosage: 9 billion CFU per capsule

Capsules per order: 30 capsules

Instructions: 1 capsule daily (morning)

Citations:

  1. Vandenplas Y, Brunser O, Szajewska H. Saccharomyces boulardii in childhood. Eur J Pediatr. 2009;168:253–265. https://pubmed.ncbi.nlm.nih.gov/19096876/
  2. Ozkan TB, Sahin E, Erdemir G, Budak F. Effect of Saccharomyces boulardii in children with acute gastroenteritis and its relationship to the immune response. J Int Med Res. 2007;35:201–212. https://pubmed.ncbi.nlm.nih.gov/17542407/
  3. Kotowska M, Albrecht P, Szajewska H. Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea in children: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther. 2005;21:583–590. https://pubmed.ncbi.nlm.nih.gov/15740542/
  4. Kollaritsch H, Holst H, Grobara P, Wiedermann G. [Prevention of traveler’s diarrhea with Saccharomyces boulardii. Results of a placebo controlled double-blind study] Fortschr Med. 1993;111:152–156. https://pubmed.ncbi.nlm.nih.gov/8486328/
  5. Bleichner G, Bléhaut H, Mentec H, Moyse D. Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients. A multicenter, randomized, double-blind placebo-controlled trial. Intensive Care Med. 1997;23:517–523. https://pubmed.ncbi.nlm.nih.gov/9201523/
  6. Cindoruk M, Erkan G, Karakan T, Dursun A, Unal S. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study. Helicobacter. 2007;12:309–316. https://pubmed.ncbi.nlm.nih.gov/17669103/
  7. Duman DG, Bor S, Ozütemiz O, Sahin T, Oğuz D, Iştan F, Vural T, Sandkci M, Işksal F, Simşek I, et al. Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to Helicobacterpylori eradication. Eur J Gastroenterol Hepatol. 2005;17:1357–1361. https://pubmed.ncbi.nlm.nih.gov/16292090/
  8. Hurduc V, Plesca D, Dragomir D, Sajin M, Vandenplas Y. A randomized, open trial evaluating the effect of Saccharomyces boulardii on the eradication rate of Helicobacter pylori infection in children. Acta Paediatr. 2009;98:127–131. https://pubmed.ncbi.nlm.nih.gov/18681892/
  9. McFarland LV, Surawicz CM, Greenberg RN, Fekety R, Elmer GW, Moyer KA, Melcher SA, Bowen KE, Cox JL, Noorani Z. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA. 1994;271:1913–1918. https://pubmed.ncbi.nlm.nih.gov/8201735/
  10. Buts JP, Corthier G, Delmee M. Saccharomyces boulardii for Clostridium difficile-associated enteropathies in infants. J Pediatr Gastroenterol Nutr. 1993;16:419–425 Buts JP, Corthier G, Delmee M. Saccharomyces boulardii for Clostridium difficile-associated enteropathies in infants. J Pediatr Gastroenterol Nutr. 1993;16:419–425. https://pubmed.ncbi.nlm.nih.gov/8315551/
  11. Surawicz CM, McFarland LV, Greenberg RN, Rubin M, Fekety R, Mulligan ME, Garcia RJ, Brandmarker S, Bowen K, Borjal D, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis. 2000;31:1012–1017. https://pubmed.ncbi.nlm.nih.gov/11049785/
  12. Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn’s disease. Dig Dis Sci. 2000;45:1462–1464. https://pubmed.ncbi.nlm.nih.gov/10961730/
  13. Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol. 2003;15:697–698. https://pubmed.ncbi.nlm.nih.gov/12840682/
  14. Bravo MV, Bunout D, Leiva L, de la Maza MP, Barrera G, de la Maza J, Hirsch S. [Effect of probiotic Saccharomyces boulardii on prevention of antibiotic-associated diarrhea in adult outpatients with amoxicillin treatment] Rev Med Chil. 2008;136:981–988. https://pubmed.ncbi.nlm.nih.gov/18949181/
  15. Effects of S. Boulardii and Amoxicillin/Clavulanate on Gut Microbiota. ClinicalTrials.gov Identifier: NCT01473368. https://classic.clinicaltrials.gov/ct2/show/results/NCT01473368?recrs=e&rslt=With&cond=Saccharomyces+boulardii&draw=2&rank=1&view=results